acyclovir valerate | 127697-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: acyclovir valerate
• 英文别名: 9-(2-Valeryloxyethoxymethyl) guanine；2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl pentanoate
• CAS: 127697-59-0
• 化学式: C₁₃H₁₉N₅O₄
• 分子量: 309.325
• InChiKey: KMTZFYVMJZEGTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  阿昔洛韦 、 戊酰氯 在 4-二甲氨基吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 acyclovir valerate
  参考文献：
  名称：

  摘要：

  Purpose. A theoretical design of percutaneous penetration enhancement in which prodrug derivation and enhancer application are combined is proposed based on the skin diffusion model and it is experimentally verified.Methods. Employing acyclovir as a model drug, the hypothesis was tested by synthesis of its prodrugs and evaluation of their in vitro permeation in the rat skin, with or without a penetration enhancer, 1-geranylazacycloheptan-2-one(GACH).Results. Among five acyclovir prodrugs, those with higher lipophilicities (propionate, butyrate, valerate, and hexanoate prodrugs) showed greater skin penetration than those of hydrophilic prodrugs (acetate), when administered in combination with GACH. Furthermore, the observed enhancement ratios were in good agreement with those predicted by theoretical consideration.Conclusions. Thus, skin permeation of prodrugs applied with an enhancer can be predicted and optimized by model analysis.

  DOI：

  10.1023/a:1016000827719

文献信息

• BCS IV类药物前药及其制备和应用
  申请人：沈阳药科大学

  公开号：CN111560018B

  公开（公告）日：2021-09-24

  本发明涉及一种BCS IV类药物前药及其制备和应用，具体涉及包括靶向肠道MCT 1载体蛋白的BCS IV类药物前药及含有该前药的药物组合物及其制备方法。该纳米粒基于纳米化与肠道转运体靶向前药的“增溶‑促渗”串联策略能够明显改善BCS IV类药物溶解性和成药性，用于口服给药。属于医药技术领域。本发明提供通式(I)所示化合物、几何异构体及其药学上可接受的盐、水合物、溶剂化物：其中，X和Drug如权利要求和说明书所述。本发明基于肠道MCT 1转运体在全肠段表达的特征，设计以MCT 1为载体的口服前药，以提高透膜性差的药物的肠细胞摄取和转运。本发明的以高分子材料为稳定剂的药物组合物体外溶出度高，可进一步解决难溶性前药的口服吸收问题。
• Therapeutic compounds
  申请人：Buroughs Welcome Co.

  公开号：US05079252A1

  公开（公告）日：1992-01-07

  The present invention relates to the valeryl ester of acyclovir and pharmacologically acceptable salts thereof and their use in medical therapy particularly in the treatment of viral infections. Also provided are processes for the preparation and pharmaceutical formulations containing the compounds according to the invention.

  本发明涉及乙酰环鸟苷的戊酰酯及其药理学上可接受的盐，以及它们在医疗治疗中，特别是在治疗病毒感染方面的应用。本发明还提供了制备该化合物的过程和含有该化合物的制药配方。
• Ester of 9-(2-hydroxyethoxymethyl) guanine
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0351215A2

  公开（公告）日：1990-01-17

  The present invention relates to the valeryl ester of acyclovir and pharmacologically acceptable salts thereof and their use in medical therapy particularly in the treatment or prophylaxis of viral infections. Also provided are processes for the preparation and pharmaceutical formulations containing the compounds according to the invention.

  本发明涉及阿昔洛韦的戊酰酯及其药理学上可接受的盐类，以及它们在医学治疗中的用途，特别是在治疗或预防病毒感染中的用途。本发明还提供了制备方法和含有本发明化合物的药物制剂。
• NMR spectral data for acyclovir prodrugs
  作者：Hongwu Gao、Ashim K. Mitra

  DOI：10.1002/(sici)1097-458x(199909)37:9<687::aid-mrc510>3.0.co;2-k

  日期：1999.9
• JPH0273086A
  申请人：——

  公开号：JPH0273086A

  公开（公告）日：1990-03-13